In AML patients, blood levels of the WT1 transcript decreased by 0.4% (mean % change from baseline, SD 2.47, range − 5.6 to 4.2) between baseline and maximum on-study measurement (n = 10), and by 1.7% (mean, SD 2.49, range − 5.6 to 0) between baseline and end of study (n = 5). This evidence concerns the gene WT1 and acute myeloid leukemia.